Ryan White Care Hepatitis C & B Language
NATAP Webinars
The Race to 2030 HCV Elimination Progress
Friday, February 7th, 2025 - 12:30pm
Click here to Register
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
CROI:
DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC...."early uptake of DoxyPEP was minimal, yet a majority of PWH were DoxyPEP eligible"
- (03/15/25)
CROI:
High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
- (03/15/25)
CROI:
The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco, Low Adherence
- (03/15/25)
CROI:
Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
- (03/14/25)
CROI:
AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques
- (03/13/25)
CROI:
HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial
- (03/13/25)
CROI:
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
- (03/13/25)
CROI:
ViiV HEALTHCARE'S INVESTIGATIONAL BROADLY NEUTRALISING ANTIBODY - N6LS - SUCCESSFULLY MAINTAINS VIRAL SUPPRESSION IN LONG-ACTING TREATMENT OF HIV
- (03/13/25)
CROI:
VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
- (03/13/25)
CROI:
Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1
- (03/13/25)
CROI:
Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: a Blinded Phase 3 Study in Adults with HIV-1
- (03/13/25)
CROI:
Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay
- (03/13/25)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
- (12/18/24)
More Hep D Articles...
Aging & Perinatally Acquired HIV
CROI:
Letermovir for CMV Suppression Improves Immunologic and Functional Aging Outcomes in Treated HIV
- (03/14/25)
CROI:
Mitochondrial DNA Variation and Physical Function among Men with and without HIV
- (03/12/25)
More Aging & HIV Articles...
PrEP
CROI:
Young Black Sexually Minoritized Men Living with HIV, Substance Use, and Syphilis Want Doxy-PEP
- (03/11/25)
CROI:
Characteristics of Breakthrough Chlamydia Cases among Cisgender Women Assigned to Doxycycline Postexposure Prophylaxis
- (03/11/25)
CROI:
Post-Exposure Prophylaxis With Doxycycline (DoxyPEP) in a Cohort of High-Risk MSM: The PRIDOX Study
- (03/11/25)
CROI:
Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Sexual Health Clinic, 2023-2024
- (03/11/25)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
CROI:
Safety and Efficacy of Glecaprevir/Pibrentasvir for 8 Weeks for Treatment of Acute Hepatitis C Virus Infection in People Living with HIV
- (03/11/25)
CROI:
Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure
- (03/11/25)
Estimating hepatitis C prevalence in the United States, 2017-2020
- (12/29/25)
Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder: 10% HCV treatment rates; African-Americans 25% less likely to be screened
- (12/28/24)
CDC and SAMHSA Leaders Encourage HIV and Viral Hepatitis Testing in Substance Use Disorder Treatment
- (12/28/24)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
- (02/25/25)
What will it take to cure hepatitis B? therapies in research
- (12/16/24)
Pathway to global elimination of hepatitis B: HBV cure is just the first step
- (12/16/24)
Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies
- (12/16/24)
More Hep B Articles...
Fatty Liver, NAFLD, NASH
AASLD:
HIGH PREVALENCE AND LOW AWARENESS OF CHRONIC LIVER DISEASE AMONG SEXUAL MINORITY MEN IN LOS ANGELES
- (12/04/24)
AASLD:
Akero Therapeutics to Showcase New Analyses of Phase 2b [efruxifermin] HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
- (12/04/24)
AASLD:
Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
- (12/04/24)
AASLD:
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
- (12/04/24)
AASLD:
Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles
- (12/04/24)
AASLD:
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study
- (12/04/24)
AASLD:
SEVEN-YEAR FOLLOW-UP OF A PREDOMINANTLY HISPANIC PATIENTS WITH SIGNIFICANT STEATOSIS AT A PRIMARY CARE CLINIC: UPDATE ON THE SOUTH BAY COHORT
- (12/04/24)
AASLD:
Hepatic steatosis in chronic hepatitis C affects the risk of hepatocellular carcinoma mainly in women
- (11/26/24)
AASLD:
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting
- (11/26/24)
AASLD:
Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis
- (11/26/24)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
https://academicmedicaleducation.com/meeting/2nd-african-workshop-women-hiv-2025
https://academicmedicaleducation.com/meeting/2nd-menopause-hiv-webinar-2025
https://www.croiconference.org
https://academicmedicaleducation.com/meeting/15th-international-workshop-women-hiv-2025
https://acthiv.org/
https://ddw.org/
https://www.easlcongress.eu/
https://asm.org/Events/ASM-Microbe/Home
IAS 2025, the 13th IAS Conference on HIV Science,
Kigali, Rwanda, July 13 to 17,
pre-conferences on 13 July.
https://www.iasociety.org/conferences/ias2025
https://academicmedicaleducation.com/meeting/26th-international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs
https://academicmedicaleducation.com/meeting/11th-international-viral-hepatitis-elimination-meeting-ivhem-2025
https://academicmedicaleducation.com/meeting/8th-conference-liver-disease-africa-colda-2025
https://www.eacsociety.org/european-aids-conference/european-aids-conference/
https://idweek.org/
https://academicmedicaleducation.com/meeting/16th-international-workshop-hiv-aging-2025
https://www.aasld.org/the-liver-meeting
https://neurohiv.com/
